Cytokine therapies in HIV infection;Immunothérapie de l'infection par le VIH par l'utilisation de cytokines: Un état des lieux

Medecine/Sciences

Volumn 22, Issue 8-9, 2006, Pages 751-754

  Lévy, Yves ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 7;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; REVIEW; T LYMPHOCYTE;

EID: 33748860240     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20062289751     Document Type: Review

References (31)

1. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995; 332: 567-75.
2. 5: results of a randomized, controlled trial. N Engl J Med 1996; 335: 1350-6.
3. Davey RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in HIV-1 infected persons. J Infect Dis 1997; 175: 781-9.
4. Levy y, Capitant C, Houhou S, et al. For the ANRS 048 study group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. Lancet 1999; 353: 1923-9.
5. Davey RT, Chaitt DJ, Albert JM, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 849-58.
6. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000; 284: 183-9.
7. Levy y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral treatment on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17: 343-51.
8. Arduino RC, Nannini EC, Rodriguez-Barradas M, et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 vanguard studies. Clin Infect Dis 2004; 39: 115-22.
9. Gougeon ML, Rouzioux C, Liberman I, et al. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patient. AIDS 2001; 15: 1729-31.
10. Farel CE, Chaitt DG, Hahn BK, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103: 3282-6.
11. + T cells. Blood 2002; 100: 2159-67.
12. + T cell expansion in HIV-infected patients is associated with long term decreases in T-cell proliferation. Blood 2004; 104: 775-80.
13. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115: 2139-48.
14. + T cells expressing foxP3 in IL-2 treated HIV-infected patients. J Clin Invest 2005; 115: 1839-47.
15. rd IAS Conference, 2005: We.Pe.16.5.B06 (abstract).
16. + regulatory T cells which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 101: 3249-56.
17. + HIV-specific T cell immune responses in vitro and are associated with favourable clinical markers of disease status. J Exp Med 2004; 200: 331-43.
18. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9: 540-7.
19. + lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003; 187: 320-5.
20. Levy Y, Gahery-Segard H, Durier C, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patient. AIDS 2005; 19: 279-86.
21. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161: 1875-82.
22. ESPRIT IL-2 trial (online) http: //www.espritstudy.org.
23. SILCAAT study design (online) http: //www.silcaatstudy.org.
24. Fry TJ, Mackall C. Interleukin-7: from bench to clinic. Blood 2002; 99: 3892-904.
25. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999; 8: 783-8.
26. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion. Implications for T cell homeastasis. Nat Med 2001; 7: 73-9.
27. Smithgall MD, Wong JG, Critchett KE, Haffar OK. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1990; 156: 2324-30.
28. Steffens CM, Managlia EZ, Landay A, Al-Harthi L. Interleukin-7 treated naïve T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 2002; 99: 3310-8.
29. Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101: 2294-9.
30. Nugeyre MT, Monceaux V, Beq S, et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol 2003; 171: 4447-53.
31. Wang FX, Xu V, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-37.